COVID-19 Pandemic and Exercise (COPE) trial: a multigroup pragmatic randomised controlled trial examining effects of app-based at-home exercise programs on depressive symptoms.
depression
exercise
randomised controlled trial
Journal
British journal of sports medicine
ISSN: 1473-0480
Titre abrégé: Br J Sports Med
Pays: England
ID NLM: 0432520
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
accepted:
13
09
2021
pubmed:
29
9
2021
medline:
6
5
2022
entrez:
28
9
2021
Statut:
ppublish
Résumé
The number of adults across the globe with significant depressive symptoms has grown substantially during the COVID-19 pandemic. The extant literature supports exercise as a potent behaviour that can significantly reduce depressive symptoms in clinical and non-clinical populations. Using a suite of mobile applications, at-home exercise, including high intensity interval training (HIIT) and/or yoga, was completed to reduce depressive symptoms in the general population in the early months of the pandemic. A 6-week, parallel, multiarm, pragmatic randomised controlled trial was completed with four groups: (1) HIIT, (2) Yoga, (3) HIIT+yoga, and (4) waitlist control (WLC). Low active, English-speaking, non-retired Canadians aged 18-64 years were included. Depressive symptoms were measured at baseline and weekly following randomisation. A total of 334 participants were randomised to one of four groups. No differences in depressive symptoms were evident at baseline. The results of latent growth modelling showed significant treatment effects in depressive symptoms for each active group compared with the WLC, with small effect sizes (ESs) in the community-based sample of participants. Treatment groups were not significantly different from each other. Effect sizes were very large (eg, week 6 ES range=-2.34 to -2.52) when restricting the analysis only to participants with high depressive symptoms at baseline. At-home exercise is a potent behaviour to improve mental health in adults during the pandemic, especially in those with increased levels of depressive symptoms. Promotion of at-home exercise may be a global public health target with important personal, social and economic implications as the world emerges scathed by the pandemic. NCT04400279.
Sections du résumé
BACKGROUND
BACKGROUND
The number of adults across the globe with significant depressive symptoms has grown substantially during the COVID-19 pandemic. The extant literature supports exercise as a potent behaviour that can significantly reduce depressive symptoms in clinical and non-clinical populations.
OBJECTIVE
OBJECTIVE
Using a suite of mobile applications, at-home exercise, including high intensity interval training (HIIT) and/or yoga, was completed to reduce depressive symptoms in the general population in the early months of the pandemic.
METHODS
METHODS
A 6-week, parallel, multiarm, pragmatic randomised controlled trial was completed with four groups: (1) HIIT, (2) Yoga, (3) HIIT+yoga, and (4) waitlist control (WLC). Low active, English-speaking, non-retired Canadians aged 18-64 years were included. Depressive symptoms were measured at baseline and weekly following randomisation.
RESULTS
RESULTS
A total of 334 participants were randomised to one of four groups. No differences in depressive symptoms were evident at baseline. The results of latent growth modelling showed significant treatment effects in depressive symptoms for each active group compared with the WLC, with small effect sizes (ESs) in the community-based sample of participants. Treatment groups were not significantly different from each other. Effect sizes were very large (eg, week 6 ES range=-2.34 to -2.52) when restricting the analysis only to participants with high depressive symptoms at baseline.
CONCLUSIONS
CONCLUSIONS
At-home exercise is a potent behaviour to improve mental health in adults during the pandemic, especially in those with increased levels of depressive symptoms. Promotion of at-home exercise may be a global public health target with important personal, social and economic implications as the world emerges scathed by the pandemic.
TRIAL REGISTRATION NUMBER
BACKGROUND
NCT04400279.
Identifiants
pubmed: 34580067
pii: bjsports-2021-104379
doi: 10.1136/bjsports-2021-104379
pmc: PMC8483923
doi:
Banques de données
ClinicalTrials.gov
['NCT04400279']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-552Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
JAMA Netw Open. 2020 Sep 1;3(9):e2019686
pubmed: 32876685
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
Can J Appl Sport Sci. 1985 Sep;10(3):141-6
pubmed: 4053261
PLoS One. 2017 Feb 2;12(2):e0170581
pubmed: 28152012
J Sport Health Sci. 2020 Jul;9(4):328-334
pubmed: 32450160
Am J Psychiatry. 2018 Jul 1;175(7):631-648
pubmed: 29690792
J Behav Med. 2016 Apr;39(2):214-24
pubmed: 26546241
J Psychiatr Res. 2016 Jun;77:42-51
pubmed: 26978184
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Sports Med. 2020 Jan;50(1):151-170
pubmed: 31541410
Int J Soc Psychiatry. 2018 Aug;64(5):427-435
pubmed: 29792097
BMJ Open Sport Exerc Med. 2021 Feb 01;7(1):e000960
pubmed: 34192010
Br J Sports Med. 2021 Sep;55(17):992-1000
pubmed: 32423912
J Clin Diagn Res. 2014 Sep;8(9):WE01-4
pubmed: 25386507
Br J Sports Med. 2020 Dec;54(24):1451-1462
pubmed: 33239350
Quant Method Psychol. 2019;15(2):96-111
pubmed: 32775313
Can Fam Physician. 2013 Mar;59(3):273-7
pubmed: 23486800
J Behav Med. 2015 Jun;38(3):460-71
pubmed: 25627668
BMC Psychiatry. 2017 Mar 20;17(1):97
pubmed: 28320380
Int J Obes (Lond). 2013 Dec;37(12):1597-602
pubmed: 23588625
PLoS One. 2015 Sep 24;10(9):e0139056
pubmed: 26402859
Sci Rep. 2021 May 13;11(1):10173
pubmed: 33986414
Can J Cardiol. 2016 Apr;32(4):495-504
pubmed: 26995692
Can J Psychiatry. 2016 Sep;61(9):576-87
pubmed: 27486153
Am J Prev Med. 1994 Mar-Apr;10(2):77-84
pubmed: 8037935
Lancet Glob Health. 2018 Oct;6(10):e1077-e1086
pubmed: 30193830
Neurosci Biobehav Rev. 2016 Feb;61:1-11
pubmed: 26657969
N Engl J Med. 2020 Aug 6;383(6):510-512
pubmed: 32283003
Int J Environ Res Public Health. 2020 May 31;17(11):
pubmed: 32486380
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037